Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Efficacy and Safety of a Defined Two-Dose Protocol of Autologous Platelet-Rich Plasma (PRP) Injection for Refractory Chronic Non-Healing Wounds: A Prospective Clinical Study

Wanchutrirat N., Jenwitheesuk K., Jenwitheesuk K., Punjaruk W., Surakunprapha P., Winaikosol K.

Prospective Study with a reported sample of 18 on Chronic Wound, published in Int Wound J (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Int Wound J (2026)
Reported sample size
18
Source database
Europe PMC
PMID
42086201
PMCID
PMC13143358
DOI
10.1111/iwj.70932

Abstract (original English)

Chronic non-healing wounds represent a major global public health challenge. Their persistence is frequently attributed to localized biological deficits that cause them unresponsive to conventional therapeutic modalities. While Platelet-Rich Plasma (PRP) has demonstrated promising results as an adjunctive treatment by delivering highly concentrated growth factors, its clinical application is currently impeded by a lack of clinical standardization, particularly optimal injection frequency, interval, and dosage. The aim of this study is to rigorously evaluate the efficacy and safety of a specific, non-intensive two-dose PRP injection protocol for accelerating the reduction of wound area in patients with various types of refractory chronic wounds. We conducted a prospective, single-arm, pretest-posttest study enrolling 18 patients with refractory non-healing wounds, defined as lesions persisting for a minimum period of 4 weeks which had failed to achieve definitive closure under optimized standard care. Autologous high-concentration PRP was injected intradermally around the wound margin at baseline (Day 0) and again 3 weeks later (Day 21). Wound area was digitally measured at baseline and subsequently at 7, 11 and 15 weeks. The primary outcome was the mean reduction in wound area (cm 2 ) at the 15-week follow-up, assessed using a Paired Samples t-test. The mean patient age was 57.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansChronic DiseaseTreatment OutcomeBlood Transfusion, AutologousProspective StudiesWound HealingAdultAgedMiddle AgedFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research